Does HRT cause weight loss?

No. HRT is approved to treat menopausal symptoms such as hot flashes and vaginal changes, not to cause weight loss, and it is not established in the evidence as a weight-loss drug [SWAN-bodycomp]. Some women find symptom relief makes healthy habits easier to sustain, but that is an indirect, individual effect, not a reason to take HRT for weight.

Is a GLP-1 better than HRT for menopause weight?

There is no trial comparing HRT against a GLP-1 for weight, so no evidence supports saying one is 'better' for that purpose. They target different problems: GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight management [FDA-Wegovy][FDA-Zepbound], while HRT treats menopausal symptoms. If weight is your goal, HRT is not the tool designed for it.

Can I take HRT and a GLP-1 at the same time?

Because they address different problems, some women are candidates for both — but that is a decision to make with a prescriber who knows your full medical history, not a general recommendation. This page explains the difference between the two; it is educational and not medical advice.

What is the difference between Wegovy, Zepbound, Ozempic and Mounjaro?

They are two molecules under different brand names by indication. Wegovy is semaglutide for weight and Ozempic is semaglutide for type 2 diabetes; Zepbound is tirzepatide for weight [FDA-Zepbound] and Mounjaro is tirzepatide for diabetes [FDA-Mounjaro]. Rybelsus is oral semaglutide for diabetes. The label indication tells you what each is officially approved to do.

Is retatrutide an option for menopause weight?

No. Retatrutide is investigational and not FDA-approved [RETA-Lancet]. It cannot be prescribed or legally purchased outside a clinical trial, so anything sold online under that name is unapproved and outside FDA oversight [FDA-GLP1-alert].

Why did I gain weight in menopause even though nothing changed?

Research following women through the menopause transition documented shifts in body composition — more fat mass, less lean mass — tied to the hormonal changes of this stage [SWAN-bodycomp]. That is why the same habits can produce a different result after 45, and why abdominal fat often becomes more noticeable.

Menopause · Compared

GLP-1 vs HRT for Menopause Weight: Two Different Tools for Two Different Problems

Educational guide · By ClearHormones Editorial Team · Updated July 2026

The most common mistake in menopause weight conversations is treating hormone replacement therapy and GLP-1 medications as competing choices. They are not. HRT is approved to treat menopausal symptoms — not weight loss — while GLP-1 drugs like Wegovy and Zepbound are FDA-approved specifically for weight management. This guide explains what each is actually designed to do, why the honest answer is often "neither replaces the other," and what the evidence does and does not support.

Key takeaways

HRT (hormone replacement therapy) is FDA-approved to treat menopausal symptoms such as hot flashes and vaginal changes — it is not approved or clinically established as a weight-loss drug.
GLP-1 medications for weight are a distinct category: Zepbound (tirzepatide) and Wegovy (semaglutide) carry FDA approval specifically for chronic weight management.
Because they target different problems — symptom relief versus appetite and weight regulation — this is rarely a true either/or decision; some people are candidates for one, the other, both, or neither.
There is no head-to-head trial comparing HRT against a GLP-1 for weight, so any claim that one 'beats' the other for weight loss is not supported by evidence.
The menopause transition itself shifts body composition toward more fat and less lean mass, which is why weight feels different after 45 even without a change in habits.
Compounded 'GLP-1' and unapproved online versions are not FDA-approved and carry safety risks flagged by the FDA.

Why menopause weight is its own problem

Weight gain around menopause is not imagined. Research tracking women through the menopause transition documented measurable shifts in body composition — more fat mass and less lean mass — that accompany the hormonal changes of this life stage [SWAN-bodycomp]. This is part of why the same eating and exercise habits that maintained your weight at 40 can stop working at 50, and why abdominal or 'belly' fat becomes more prominent for many women.

This matters for the GLP-1-versus-HRT question because the two interventions engage with this reality from completely different angles. One aims to relieve the symptoms driven by declining estrogen. The other aims to change appetite and how the body regulates weight. Understanding that split is the single most useful thing you can take from this page. If your main concern is where the weight is sitting, our companion guide on menopause belly fat goes deeper on the body-composition side.

What HRT is — and what it is not

Hormone replacement therapy replaces estrogen (and often progesterone) to treat the symptoms of menopause: hot flashes, night sweats, and genitourinary changes are the classic indications. That is the job it is approved and prescribed to do. It is important to be direct about the limit here: HRT is not an FDA-approved weight-loss treatment, and it is not established in the evidence as a drug you take to lose weight [SWAN-bodycomp].

Some women feel that managing menopausal symptoms makes it easier to sleep, move, and stay consistent with the habits that influence weight — but that is an indirect, individual effect, not a weight-loss mechanism you can count on. Anyone selling HRT primarily as a way to drop pounds is overstating what the therapy is for. If symptom relief is your goal, HRT is a legitimate conversation to have with a clinician; if weight is the goal, HRT is the wrong tool to reach for first.

What GLP-1 medications are — and how approvals differ

GLP-1 (and GLP-1/GIP) medications are a separate category built around appetite and metabolic regulation. Two are FDA-approved for chronic weight management: Zepbound (tirzepatide) and Wegovy (semaglutide) [FDA-Zepbound][FDA-Wegovy]. The same molecules are also sold under different brand names for type 2 diabetes — Mounjaro is tirzepatide for diabetes [FDA-Mounjaro], Ozempic is semaglutide for diabetes, and Rybelsus is oral semaglutide for diabetes. The approval on the label is what determines what a drug is officially indicated to do, so the brand name matters.

In pivotal obesity trials, semaglutide (STEP-1) and tirzepatide (SURMOUNT-1) each produced clinically meaningful weight loss versus placebo in people with overweight or obesity [STEP-1][SURMOUNT-1]. These are the trials that earned the weight-management approvals. Retatrutide, a triple-agonist still in development, has shown weight effects in trials [RETA-Lancet] but is investigational and not FDA-approved — it cannot be prescribed or legally bought outside a clinical trial, so it is not a real option for a decision you are making today.

The head-to-head question, answered honestly

People want a clean answer: which one wins for weight? The honest answer is that no trial has ever compared HRT against a GLP-1 for weight loss, so there is no head-to-head result to report. Anyone who gives you a percentage or a 'this one is X% better' figure for that matchup is inventing it.

Even within the GLP-1 world, direct comparisons are rare. The one genuine head-to-head trial in this space put tirzepatide against semaglutide — but it was conducted in people with type 2 diabetes, not as a weight-loss study, and its endpoint was glucose control [SURPASS-2]. For broader cross-drug context, a network meta-analysis has compared weight-loss drugs indirectly, pooling separate trials rather than testing drugs against each other in one study [BMJ-meta]. Indirect comparison is useful, but it is not the same as a head-to-head, and it does not include HRT as a weight drug because HRT is not one.

Why it is not really either/or

Because HRT and GLP-1 medications solve different problems, framing them as rivals leads to the wrong decision. A woman with disruptive hot flashes and no weight concern is a candidate for the HRT conversation and has no particular reason to start a GLP-1. A woman whose main issue is weight and appetite, with mild or no menopausal symptoms, is looking at the GLP-1 conversation, and HRT would not address her goal. A third woman may have both problems — and in that case the two are considered separately, each on its own merits, not swapped one for the other.

So the practical move is to separate the questions before you decide anything. Ask: what is actually bothering me — symptoms, weight, or both? Then match each concern to the tool designed for it, and take each to a clinician as its own decision. This is a decision to make with a prescriber who can weigh your history; the sections above are meant to frame the questions, not to tell you which drug to take.

Safety, compounding, and the online market

Whichever direction you explore, the source of the medication matters as much as the molecule. The FDA has specifically warned about unapproved and compounded GLP-1 products sold for weight loss, citing dosing errors and safety concerns; compounded versions are not FDA-approved products [FDA-GLP1-alert]. The vials and 'research' powders marketed online — including anything sold as retatrutide — sit outside the approval and oversight that make the branded medications what they are.

The takeaway is not to be scared off legitimate, prescribed treatment, but to insist on it. An FDA-approved medication obtained through a licensed prescriber and pharmacy is a fundamentally different thing from an unregulated online product that borrows the same name. If you want to see which approved medications exist and how the brands map to their molecules and indications, start with our medications overview and brands directory rather than a marketplace.

When to see a healthcare provider

Any claim that HRT is a weight-loss treatment — it is approved for menopausal symptoms, not weight.
A specific percentage or 'X% more effective' figure for HRT versus a GLP-1 — no head-to-head trial exists, so any such number is invented.
Retatrutide sold as vials or powder online — it is investigational, not FDA-approved, and cannot be legally bought outside a clinical trial.
Compounded or 'research-grade' GLP-1 products marketed for weight loss — the FDA has warned these are unapproved and carry safety risks.
A named doctor or clinic promising a specific weight-loss number from either drug — outcomes vary and specific figures for this comparison are not in the evidence.

If symptoms are severe or sudden, contact your primary-care provider, OB/GYN, or a telehealth clinician for same-day evaluation. Browse providers with same-day visits.

Affiliate link Advertiser Disclosure: This site is reader-supported. We may earn an affiliate commission when you sign up for a service through links on our site. This does not influence our editorial recommendations or medical reviews. Read our full disclosure.

Frequently asked questions

Does HRT cause weight loss?: No. HRT is approved to treat menopausal symptoms such as hot flashes and vaginal changes, not to cause weight loss, and it is not established in the evidence as a weight-loss drug [SWAN-bodycomp]. Some women find symptom relief makes healthy habits easier to sustain, but that is an indirect, individual effect, not a reason to take HRT for weight.
Is a GLP-1 better than HRT for menopause weight?: There is no trial comparing HRT against a GLP-1 for weight, so no evidence supports saying one is 'better' for that purpose. They target different problems: GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight management [FDA-Wegovy][FDA-Zepbound], while HRT treats menopausal symptoms. If weight is your goal, HRT is not the tool designed for it.
Can I take HRT and a GLP-1 at the same time?: Because they address different problems, some women are candidates for both — but that is a decision to make with a prescriber who knows your full medical history, not a general recommendation. This page explains the difference between the two; it is educational and not medical advice.
What is the difference between Wegovy, Zepbound, Ozempic and Mounjaro?: They are two molecules under different brand names by indication. Wegovy is semaglutide for weight and Ozempic is semaglutide for type 2 diabetes; Zepbound is tirzepatide for weight [FDA-Zepbound] and Mounjaro is tirzepatide for diabetes [FDA-Mounjaro]. Rybelsus is oral semaglutide for diabetes. The label indication tells you what each is officially approved to do.
Is retatrutide an option for menopause weight?: No. Retatrutide is investigational and not FDA-approved [RETA-Lancet]. It cannot be prescribed or legally purchased outside a clinical trial, so anything sold online under that name is unapproved and outside FDA oversight [FDA-GLP1-alert].
Why did I gain weight in menopause even though nothing changed?: Research following women through the menopause transition documented shifts in body composition — more fat mass, less lean mass — tied to the hormonal changes of this stage [SWAN-bodycomp]. That is why the same habits can produce a different result after 45, and why abdominal fat often becomes more noticeable.

Primary sources

ClearHormones publishes editorial health information for education only — not medical advice.